BIOMAT Database Logo BIOMAT Database Logo

Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virus. 1993

C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660.

The effect on immunologic and virological parameters of up to 24 weeks of therapy with didanosine at daily oral doses of < or = 12.5 mg/(kg.d) was studied retrospectively in 69 patients with advanced disease due to human immunodeficiency virus--i.e., AIDS or advanced AIDS-related complex--who had previously been treated with zidovudine. Patients entered the study with a low CD4 cell count (median, 39/microL) and with evidence of an ongoing depression of bone marrow function. Didanosine therapy was associated with a significant increase in CD4 counts and a prolonged decrease in serum levels of p24 antigen relative to baseline. These changes were more pronounced in the population with baseline CD4 counts of > or = 100/microL. A beneficial effect of didanosine therapy on hematologic parameters was observed in these patients, with increases during therapy of hemoglobin levels as well as white blood cell, granulocyte, and platelet counts. These responses were maximal at weeks 16-20. Further investigations are needed to establish the clinical correlates of these observations.

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D005260 Female Females
D006454 Hemoglobins The oxygen-carrying proteins of ERYTHROCYTES. They are found in all vertebrates and some invertebrates. The number of globin subunits in the hemoglobin quaternary structure differs between species. Structures range from monomeric to a variety of multimeric arrangements. Eryhem,Ferrous Hemoglobin,Hemoglobin,Hemoglobin, Ferrous
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection.
February 1994, Pediatrics,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Continued zidovudine or didanosine for human immunodeficiency virus infection.
November 1992, The New England journal of medicine,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
February 2001, AIDS research and human retroviruses,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
February 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
May 1997, The New England journal of medicine,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.
July 1994, The Journal of pediatrics,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
Cytomegalovirus retinitis under combination therapy with zidovudine and dideoxycytidine in advanced human immunodeficiency virus infection.
November 1993, German journal of ophthalmology,
C McLaren, and M Rozencweig, and M Beltangady, and C Nicaise, and R Yarchoan, and R Dolin, and J D Allan, and T P Cooley, and M Seidlin, and L F Smaldone
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
January 1994, The Journal of infectious diseases,
Copied contents to your clipboard!